EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, INCY:

05 Sep 2025
LAST:

86.64

CHANGE:
 1.20		OPEN:
85.48		HIGH:
86.69		ASK:
118.00		VOLUME:
1.39M
CHG(%):
1.40		PREV:
85.44		LOW:
85.06		BID:
83.18		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Sep 2585.4886.6985.0686.641.39M
04 Sep 2587.2687.9985.4285.442.25M
03 Sep 2585.9287.4685.7286.961.99M
02 Sep 2584.9787.9984.9685.982.21M
29 Aug 2583.8584.6383.4184.611.34M
28 Aug 2584.2684.5983.5083.701.01M
27 Aug 2584.1385.1284.1384.841.46M
26 Aug 2584.7184.7183.6684.002.33M
25 Aug 2584.8885.8784.4384.761.64M
22 Aug 2587.0087.0084.9085.041.48M

COMPANY PROFILE

Name:
About:Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Sector:Healthcare
Industry:Biotechnology
Address:1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Website:https://www.incyte.com
CUSIP:45337C102
CIK:0000879169
ISIN:US45337C1027
FIGI:BBG000BNPSQ9
LEI:549300Z4WN6JVZ3T4680

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:20.20
Price to Book:3.98
Price to Sales:3.64
EBITDA:1.061B
Shares:195.28M
Market Cap:16.919B

TECHNICAL INDICATORS

MA5:85.93
MA10:85.20
MA20:84.66
MA50:76.55
MA100:70.29
MA200:69.66
STO9:68.53
STO14:68.53
RSI14:49.01
WPR14:-9.82
MTM14:1.72
ROC14:0.02
ATR:1.74
Week High:87.99
Week Low:83.41
Month High:87.99
Month Low:76.45
Year High:87.99
Year Low:53.56
Volatility:3.64

RECENT SPLITS

Date Ratio
01 Sep 20002-1
10 Nov 19972-1